A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma

Summary

This research study is studying Blinatumomab as a possible treatment for Indolent Non-Hodgkin Lymphoma (NHL).

Timeline

Start

2016-08

Primary completion

2020-01-27

Completion

2023-12

Outcome

Outcome not reported

Stopped (Enrollment): “Study closed early due to slow accrual”

Drugs

Indications